Focal Medical, Inc.

06/04/2025

One of our goals is to reduce our tech to a wearable so we can join this next stage of cancer care.

Mayo Clinic takes cancer care beyond walls and into patients’ homes.

06/04/2025

Focal Medical is now Continuity Biosciences!

/PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a...

09/26/2024

Focal Medical, Inc. spent a very productive day at the RESI conference in Boston yesterday attending panels and speaking with investors as we raise our next round to help fund our IND-cleared clinical trial for locally advanced unresectable pancreatic cancer.

07/26/2024

Essential research!!

Mayo Clinic researchers' early findings suggest that capturing the subtle yet significant body changes that occur as pancreatic cancer develops could be a key strategy in the fight against the disease.

03/06/2024

Focal Medical has received a $300,000 award from the National Cancer Institute to develop treatment for oral cavity cancer.

Read more here!

Cary, North Carolina — Focal Medical, Inc., (“Focal”) a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced that it has received a $300,000 award from the National Cancer Institute (NCI) ...

01/30/2024

We are pleased to announce that Ness Bermingham, Ph.D., operating partner at Khosla Ventures and founder of Intellia Therapeutics, has joined our Board of Directors!

Dr. Bermingham is a serial biotech entrepreneur and investor in companies with diverse technology platforms including those developing novel delivery systems. We look forward to Dr. Bermingham’s contributions to the growth and development of our company.

Learn more here: https://focalmedical.co/2024/01/focal-medical-provides-business-update/

01/13/2024

Two people might have the same type of cancer, but their diseases can behave differently. That is why precision medicine is needed.

01/09/2024

According to The American Cancer Society, the incidence of pancreatic cancer in the U.S. is more than 62,000 cases annually and it represents the third leading cause of cancer death. At diagnosis, the advanced stage of the cancer and the complex interface between the pancreas and adjacent organs often preclude surgical resection.

Patients whose tumors are resectable have the best chance for cure and, for these patients, surgical resection with or without neoadjuvant chemotherapy, is the standard of care. Treatment options for locally advanced nonresectable tumors comprise a variety of systemic chemotherapy regimens, which are rarely curative unless there is dramatic response to chemotherapy that allows the tumor to be resected.

In our lead program, we are targeting locally advanced nonresectable pancreatic cancer and are shifting the paradigm in how therapy is delivered. We empower gemcitabine (an FDA approved chemotherapeutic) to deliver its anti-cancer effect directly to the tumor precisely and specifically with the goal to reduce tumor burden and restage nonresectable tumors to resectable.

To learn more about the pancreatic cancer nonresectable medical need, visit: https://focalmedical.co/applications/

01/09/2024

Exciting News! Focal Medical has received FDA clearance of an IND application to initiate a Phase 1b clinical trial of the Company’s first targeted therapeutic product, ACT-IOP-003.

The trial will evaluate the safety and tolerability of targeted delivery of gemcitabine to locally advanced nonresectable (LANR) pancreatic tumors. ACT-IOP-003 demonstrated dramatic results in an orthotopic patient-derived xenograft murine model of human pancreatic cancer in which 100% of treated tumors averaged 40% volume reduction.

The study is expected to start mid-2024.

For more details on the clearance and to learn more about ACT-IOP-003, read the full news release here:
https://www.businesswire.com/news/home/20240109845617/en/Focal-Medical-Receives-FDA-Clearance-to-Initiate-Phase-1b-Clinical-Trial-of-ACT-IOP-003-a-Targeted-Therapeutic-Product-in-Development-for-Pancreatic-Cancer